Xofluza (baloxavir marboxil) met its primary endpoint in the CENTERSTONE trial, reducing the odds of untreated household ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, shares his key takeaways from Cencora’s ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, highlights recent ICH guidelines and how ...

In addition to meeting the primary endpoint of superior A1C reduction, the once-daily oral pill reduced weight by an average ...

Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, talks AI and how change is needed for the ...